Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Clinical trial NCT03997123 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03997123
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-25
- Primary completion
- 2026-03-16
- Enrollment
- 923
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.